关于江西新赣江药业股份有限公司 2022 年年度股东大会的 北京德恒（杭州）律师事务所 法律意见 杭州市上城区新业路 200 号华峰国际商务大厦 10-11 楼 电话:0571-86508080 传真:0571-87357755 邮编：310020 北京德恒（杭州）律师事务所 关于江西新赣江药业股份有限公司 2022 年年度股东大会的法律意见 北京德恒（杭州）律师事务所 关于江西新赣江药业股份有限公司 2022 年年度股东大会的 法律意见 德恒 12G20230094-1 号 致：江西新赣江药业股份有限公司 根据《中华人民共和国公司法》（以下简称《公司法》）《中华人民共和国 证券法》（以下简称《证券法》）《北京证券交易所股票上市规则（试行）》《北 京证券交易所上市公司持续监管办法（试行）》《上市公司股东大会规则（2022 修订）》等法律、法规和其他有关规范性文件的要求，北京德恒（杭州）律师事 务所（以下简称"本所"）接受江西新赣江药业股份有限公司（以下简称"公司"） 的委托，指派律师（以下简称"本所律师"）出席公司 2022 年年度股东大会（以 下简称"本次股东大会"），并出具本《法律意见》。 本《法律意见》 ...

特此公告！ 集体接待日活动的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 为进一步加强与投资者的互动交流,江西新赣江药业股份有限公司(以下简 称"公司")将参加由江西证监局、江西省上市公司协会与深圳市全景网络有限 公司联合举办的"2023 年江西辖区上市公司投资者集体接待日活动",现将相关 事项公告如下: 本次活动将采用网络远程的方式举行,投资者可登录"全景路演"网站 （https://rs.p5w.net/）,或关注微信公众号:全景财经,或下载全景路演 APP, 参与本次互动交流,活动时间为 2023 年 5 月 19 日(周五)14：30-17:00。届时公 司董事会秘书严棋鹏先生将在线就公司 2022 年度业绩、公司治理、发展战略、 经营状况、可持续发展等投资者关心的问题,与投资者进行沟通与交流,欢迎广大 投资者踊跃参与! 证券代码：873167 证券简称：新赣江 公告编号：2023-053 江西新赣江药业股份有限公司 关于参加 2023 年江西辖区上市公司投资者 江西新赣江药业股份有限公 ...

证券代码：873167 证券简称：新赣江 公告编号：2023-052 江西新赣江药业股份有限公司 投资者关系活动记录表 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 □分析师会议 □路演活动 □其他（请文字说明其他活动内容） 二、投资者关系活动情况 一、投资者关系活动类别 □特定对象调研 ☑业绩说明会 □媒体采访 □现场参观 □新闻发布会 （一）活动时间、地点 公司于 2023 年 5 月 11 日（星期四）下午 15:00-17:00 通过全景网"投资 者关系互动平台"（http://ir.p5w.net）采用网络方式召开 2022 年年度业绩说 明会。 （二）参与单位及人员 通过网络方式参加公司 2022 年年度报告业绩说明会的投资者。 （三）上市公司接待人员 公司总经理：刘晓鹏先生 公司董事会秘书：严棋鹏先生 财务负责人：曹爱平先生 公司保荐代表人：顾磊先生 三、投资者关系活动主要内容 本次业绩说明会通过年报视频解读等形式对公司情况及 2022 年经营业绩情 况进行了介绍。同时，公司就投资者在本 ...

2022 年度报告业绩说明会预告公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、 说明会类型 江西新赣江药业股份有限公司(以下简称"公司")于 2023 年 4 月 26 日 在北京证券交易所官方信息披露平台((http://www.bse.cn/)发布了《江西新 赣江药业股份有限公司 2022 年年度报告》及《江西新赣江药业股份有限公司 2022 年年度报告摘要》，为方便广大投资者更深入了解公司 2022 年年度经营 业绩的具体情况，加强与投资者的互动交流，公司拟召开 2022 年年度报告业 绩说明会。 二、 说明会召开的时间、地点 证券代码：873167 证券简称：新赣江 公告编号：2023-051 江西新赣江药业股份有限公司 公司董事会秘书:严棋鹏先生 公司财务负责人:曹爱平先生 公司保荐代表人:顾磊先生 四、 投资者参加方式 本次说明会采用网络方式召开。 （一）会议召开时间：2023 年 5 月 11 日(周四)15:00-17:00。 （二）会议召开地点 会议召开地点本次业绩说明会将 ...

证券代码：873167 证券简称：新赣江 公告编号：2023-051 江西新赣江药业股份有限公司 2022 年度报告业绩说明会预告公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、 说明会类型 江西新赣江药业股份有限公司(以下简称"公司")于 2023 年 4 月 26 日 在北京证券交易所官方信息披露平台((http://www.bse.cn/)发布了《江西新 赣江药业股份有限公司 2022 年年度报告》及《江西新赣江药业股份有限公司 2022 年年度报告摘要》，为方便广大投资者更深入了解公司 2022 年年度经营 业绩的具体情况，加强与投资者的互动交流，公司拟召开 2022 年年度报告业 绩说明会。 二、 说明会召开的时间、地点 （一）会议召开时间：2023 年 5 月 11 日(周四)15:00-17:00。 （二）会议召开地点 会议召开地点本次业绩说明会将采用网络远程的方式举行，投资者可登录 全景网"投资者关系互动平台"（https://ir.p5w.net）参与本次年度业绩说明 会。 ...

一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2023 年 4 月 27 日 2.会议召开地点：公司会议室 3.会议召开方式：现场+通讯 4.发出董事会会议通知的时间和方式：2023 年 4 月 13 日以书面方式发出 证券代码：873167 证券简称：新赣江 公告编号：2023-048 江西新赣江药业股份有限公司 第二届董事会第二十次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 5.会议主持人：董事长张爱江先生 6.会议列席人员：严棋鹏、刘荆平、单慧琳 7.召开情况合法、合规、合章程性说明： 本次会议召集、召开、议案审议程序符合有关法律、行政法规、部门规章、 规范性文件和《公司章程》的规定。 （二）会议出席情况 会议应出席董事 7 人，出席和授权出席董事 7 人。 二、议案审议情况 （一）审议通过《2023 年第一季度报告》 1.议案内容： 具体内容详见于同日在北京证券交易所信息披露平台（www.bse.cn）披露 的《2023 年第一季度报告》（公告编号:2023-0 ...

Financial Performance - Net profit attributable to shareholders rose by 27.35% to CNY 16,679,264.59 for the first quarter of 2023[9] - Operating revenue increased by 25.39% to CNY 69,223,571.97 year-on-year[9] - Total operating revenue for Q1 2023 reached ¥69,223,571.97, an increase from ¥55,206,584.18 in Q1 2022, representing a growth of approximately 25.5%[38] - Total revenue for Q1 2023 was CNY 54,998,310.76, compared to CNY 49,831,078.54 in Q1 2022, indicating a growth of about 10.4%[41] - Net profit for Q1 2023 reached CNY 17,163,144.48, compared to CNY 12,923,439.52 in Q1 2022, marking an increase of about 32.5%[39] - The company reported a total comprehensive income of CNY 17,163,144.48 for Q1 2023, compared to CNY 12,923,439.52 in Q1 2022, reflecting an increase of about 32.5%[39] - Basic and diluted earnings per share for Q1 2023 were both CNY 0.29, up from CNY 0.26 in Q1 2022, reflecting an increase of approximately 11.5%[39] Assets and Liabilities - Total assets increased by 44.17% to CNY 510,167,699.87 compared to the end of the previous year[9] - The company's total liabilities decreased to ¥46,180,127.01 from ¥71,186,539.18, a reduction of approximately 35%[32] - The company has a total liability of ¥29,212,343.92 as of March 31, 2023, down from ¥47,750,231.20 at the end of 2022, reflecting a reduction in financial obligations[36] - The company's equity increased from ¥51,225,000.00 to ¥70,861,250.00, showing a growth of around 38%[32] - Shareholders' equity totaled ¥465,620,651.14 as of March 31, 2023, up from ¥285,701,188.30 at the end of 2022, indicating a growth of about 63.0%[37] Cash Flow - Cash flow from operating activities decreased by 115.99% to CNY -2,711,385.11 due to increased tax payments and employee wages[11] - The net cash flow from operating activities for Q1 2023 was negative at CNY -2,711,385.11, a significant decrease from CNY 16,952,900.64 in Q1 2022[43] - The net cash flow from investment activities was 24,209,242.95 CNY, compared to a negative cash flow of -316,139.27 CNY in the previous year[44] - The total cash inflow from financing activities amounted to 172,488,630.84 CNY, while cash outflow was 3,511,500.00 CNY, resulting in a net cash flow of 168,977,130.84 CNY[44] - The net increase in cash and cash equivalents for the period was 190,474,988.68 CNY, leading to a closing balance of 248,335,743.27 CNY[44] - Cash and cash equivalents as of March 31, 2023, were ¥206,900,163.02, significantly higher than ¥42,661,323.90 at the end of 2022, showing improved liquidity[35] Shareholder Information - The number of ordinary shareholders increased to 4,337, reflecting a growing investor interest[15] - The largest shareholder, Zhang Aijiang, holds 34,857,012 shares, representing 49.19% of total shares[17] - Zhang Ming is the second-largest shareholder with 4,980,946 shares, accounting for 7.03%[17] - The total shares held by the top ten shareholders amount to 53,482,928, which is 75.48% of the total[18] Expenses and Costs - Sales expenses increased by 74.14% due to higher logistics and advertising costs[11] - Total operating costs for Q1 2023 were ¥48,794,022.30, up from ¥39,421,157.99 in Q1 2022, indicating an increase of about 23.5%[38] - Operating costs for Q1 2023 were CNY 26,439,104.07, an increase from CNY 23,998,662.33 in Q1 2022, which is a rise of approximately 10.1%[41] - The company incurred a tax expense of CNY 3,308,216.02 in Q1 2023, compared to CNY 2,311,165.99 in Q1 2022, which is an increase of approximately 43.2%[39] Commitments and Compliance - The company has committed to repurchase shares and compensate investors due to false statements, which is currently being fulfilled[24] - The company has also committed to avoid fund occupation and is in compliance with this commitment[24] - The company has made commitments to reduce and regulate related party transactions, which are currently being fulfilled[24] - The company is currently fulfilling its lock-up commitments made on March 16, 2022[22] Other Information - The company has no ongoing litigation or arbitration matters during the reporting period[21] - There are no external guarantees or loans provided by the company[21] - The company has not engaged in any significant related party transactions during the reporting period[21] - There are no assets under seizure, detention, or freezing[21] - The company has not been subject to any investigations or penalties[21] - The company has not executed any share repurchase plans during the reporting period[21] - The company reported a decrease in accounts payable from ¥15,099,488.18 in Q1 2022 to ¥12,975,603.62 in Q1 2023, suggesting improved payment practices[36] - Research and development expenses for Q1 2023 were ¥2,593,476.93, slightly higher than ¥2,358,891.29 in Q1 2022, indicating continued investment in innovation[38] - The increase in long-term equity investments from ¥22,474,586.75 at the end of 2022 to ¥65,883,184.13 as of March 31, 2023, indicates a strategic focus on expanding investment portfolios[35]

证券代码：873167 证券简称：新赣江 公告编号：2023-049 江西新赣江药业股份有限公司 第二届监事会第十三次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、会议召开和出席情况 5.会议主持人：张燕文先生 6.召开情况合法、合规、合章程性说明： 本次监事会会议的召集、召开、议案审议程序符合《公司法》等相关法律、 行政法规、部门规章、规范性文件及《公司章程》的有关规定。 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 二、议案审议情况 （一）会议召开情况 本议案不涉及关联交易事项，无需回避表决。 本议案无需提交股东大会审议。 （一）审议通过《2023 年第一季度报告》议案 1.议案内容： 具体内容详见于同日在北京证券交易所信息披露平台（www.bse.cn）披露 的《2023 年第一季度报告》（公告编号:2023-050）。 1.会议召开时间：2023 年 4 月 27 日 2.会议召开地点：公司小会议室 3.会议召开方式：现场 4.发出监事会会议通知的 ...

证券代码：873167 证券简称：新赣江 公告编号：2023-042 江西新赣江药业股份有限公司 2022 年年度权益分派预案公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 江西新赣江药业股份有限公司（以下简称"公司"）于 2023 年 4 月 25 日 召开第二届董事会第十九次会议、第二届监事会第十二次会议，审议通过《关 于 2022 年年度利润分配预案的议案》，本议案尚需公司 2022 年年度股东大会 批准。现将有关情况公告如下： 一、权益分派预案情况 根据公司 2023 年 4 月 26 日披露的 2022 年年度报告（财务报告已经审计）， 截至 2022 年 12 月 31 日，上市公司合并报表归属于母公司的未分配利润为 74,388,708.90 元，母公司未分配利润为 81,590,867.36 元。 公司本次权益分派预案如下：公司目前总股本为 70,861,250 股，以未分配利 润向全体股东每 10 股派发现金红利 2.5 元（含税）。本次权益分派共预计派发现 金红利 17,715 ...

Recognition and Awards - The company was awarded the title of "National Intellectual Property Advantage Enterprise" by the National Intellectual Property Administration in October 2022[3]. - In November 2022, the company was recognized as a "High-tech Enterprise" by the Jiangxi Provincial Department of Science and Technology, Jiangxi Provincial Department of Finance, and the State Taxation Administration Jiangxi Provincial Taxation Bureau[4]. - The company is recognized as a "high-tech enterprise" and has achieved provincial-level recognition for its specialized and innovative capabilities[47]. Financial Performance - The company's operating revenue for 2022 was CNY 211,150,421.69, representing a year-on-year increase of 1.56% compared to CNY 207,913,346.74 in 2021[28]. - The net profit attributable to shareholders for 2022 was CNY 46,322,272.63, a decrease of 15.50% from CNY 54,830,811.11 in 2021[28]. - The gross profit margin for 2022 was 46.07%, up from 44.02% in 2021[28]. - Total assets increased by 25.47% to CNY 353,875,321.26 at the end of 2022, compared to CNY 282,032,972.79 at the end of 2021[30]. - Total liabilities rose by 56.45% to CNY 71,186,539.18 at the end of 2022, compared to CNY 45,496,463.44 at the end of 2021[30]. - The company's net assets attributable to shareholders increased by 19.95% to CNY 278,499,029.84 at the end of 2022, compared to CNY 232,176,757.21 at the end of 2021[30]. - The basic earnings per share for 2022 was CNY 0.90, down from CNY 1.08 in 2021, reflecting a decrease of 15.50%[28]. - The company's debt-to-asset ratio (consolidated) was 20.12% at the end of 2022, compared to 16.13% at the end of 2021[30]. - The net cash flow from operating activities for 2022 was ¥89,419,311.08, an increase of 90.49% compared to ¥46,941,334.18 in 2021[32]. - The total asset growth rate for 2022 was 25.47%, recovering from a decline of 4.95% in 2021[33]. - The operating profit for 2022 was CNY 53,831,867.72, a decrease of 12.99% year-on-year, while net profit was CNY 46,152,272.73, down 13.33% year-on-year[48]. Risk Management - The company faces risks related to fluctuations in raw material prices, which significantly impact its profitability due to the high proportion of direct materials in production costs[10]. - The company has established a comprehensive internal control system to mitigate risks associated with governance and operational complexities as it expands its production and sales scale[11]. - The company has completed a systematic analysis of major risk factors, with certain risks no longer classified as significant, such as the risk of not fully paying social insurance and housing funds for all employees[12]. - The company has established a strict procurement system to ensure the quality of raw materials, adhering to GMP management standards[40]. - The company has engaged a qualified third-party organization to establish a robust quality control and monitoring system[71]. - The company has implemented a robust fundraising management system to address risks related to the feasibility of investment projects, which are influenced by market conditions and technological developments[138]. Regulatory Environment - The National Development and Reform Commission announced the cancellation of government pricing for drugs, allowing market competition to determine actual transaction prices[59]. - The Drug Administration Law emphasizes fair pricing practices and prohibits price monopolies and fraud in drug pricing[59]. - The implementation of the Drug Registration Management Measures aims to streamline the approval process for new drugs and generics[63]. - The new regulations eliminate GMP and GSP certifications, simplifying the approval process while maintaining high drug quality standards[70]. - The implementation of a drug marketing authorization holder system shifts the primary responsibility for drug quality from manufacturers to the marketing authorization holders[70]. - The new regulatory environment emphasizes a shift from threshold-based management to a focus on regulatory oversight[70]. Research and Development - The company has made significant investments in research and development, although specific figures were not disclosed in the provided content[114]. - R&D expenditure for the current period is ¥8,862,117.87, representing 4.20% of operating income, an increase from 3.95% in the previous period[106]. - The total number of patents owned by the company increased from 40 to 53, with invention patents rising from 5 to 8[109]. - The company is advancing several R&D projects, including the consistency evaluation of Metronidazole tablets and the development of new drugs like Dexamethasone and Acetaminophen, aimed at improving product quality and market competitiveness[110]. - The company is developing new health food products, including enzyme and selenium-rich products, to expand its product line and market presence[112]. Environmental Compliance - The company has been proactive in enhancing its environmental protection measures in response to stricter national standards, which may increase operational costs[11]. - The company has maintained a focus on environmental protection, complying with national laws and regulations, and investing in waste treatment facilities[126]. - The company is preparing for potential future regulatory changes regarding environmental standards, which may increase its environmental compliance costs[126]. - The company faces risks from stricter environmental regulations, which may increase production costs and require further investment in pollution control measures[136]. Shareholder Commitments - The actual controller and major shareholders made a lock-up commitment on March 16, 2022, stating they will not transfer or entrust others to manage their shares for 12 months after the listing of Xin Gan Jiang stock[148]. - The company has committed to strict adherence to promises made during the public offering process, with penalties for non-compliance including public apologies and compensation for investor losses[171]. - The actual controller and major shareholders have pledged to compensate for any losses incurred by the company or investors due to non-fulfillment of commitments, with restrictions on share transfers until obligations are met[172]. - The company has committed to ensuring the accuracy and completeness of its public disclosures, taking legal responsibility for any inaccuracies[181]. Operational Strategies - The company plans to adapt its business strategies to comply with new regulatory requirements and address market competition challenges[13]. - The company aims to strengthen its sales team by recruiting industry sales elites and optimizing the sales system to promote sustainable growth in its main business[132]. - The company intends to leverage capital markets for external expansion, focusing on mergers and acquisitions to enhance its market position and operational scale[132]. - The company is actively expanding its integrated business from raw materials to formulations, focusing on strategic development of unique products such as Duzhong Qiang Bone Capsules and Compound Yinqiao Anmin Capsules[130].